| 1 |
Boundless Bio breaks IPO lull with $100M fundraise |
| 2 |
FDA approves Merck lung disease drug acquired in $11B deal |
| 3 |
European study finds popular ALS drug ineffective |
| 4 |
Viking stays in obesity drug race with early data for weight loss pill |
| 5 |
10 clinical trials to watch in the first half of 2024 |
| 6 |
Biotech IPOs are the industry’s lifeblood. Track how they’re performing. |
| 7 |
The future of companion diagnostic (CDx) development: Why commercialization is key |
| 8 |
SQZ, Portal founder Armon Sharei on starting over in biotech |
| 9 |
Moderna gets Blackstone backing for flu vaccine R&D |
| 10 |
Supreme Court weighs abortion opponents’ standing in mifepristone case |
| 11 |
Stoke shares surge on updated results for Dravet drug |
| 12 |
Biotech M&A is on the upswing. Track the latest deals here. |
| 13 |
FDA rejects Regeneron lymphoma drug, setting back company’s oncology push |
| 14 |
AbbVie to buy immune drug developer Landos |
| 15 |
Axsome drug succeeds in narcolepsy symptoms trial |
| 16 |
Novo to acquire heart failure drug in $1B deal for Cardior |
| 17 |
FDA clears first-of-its-kind Duchenne drug for broad use |
| 18 |
Bayer streamlines pharma leadership team amid company shakeup |
| 19 |
Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off |
| 20 |
Roche autoimmune disease drug disappoints in closely watched trial |
| 21 |
NextCure to lay off 37% of staff, dial back research plans |
| 22 |
Orchard sets out to sell world’s priciest gene therapy |
| 23 |
Acelyrin eye drug heads to late-stage testing after trial win |
| 24 |
Clasp launches with $150M and a plan for precision cancer immunotherapies |
| 25 |
Capstan heats up ‘in vivo’ cell therapy chase with $175M fundraise |
| 26 |
AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion |
| 27 |
With new data, Bayer readies rival to Astellas menopause drug |
| 28 |
Engrail’s precision psychiatry drugs get more buy in from venture investors |
| 29 |
Orchard follows buyout with FDA approval of rare disease gene therapy |
| 30 |
BioPharma Dive news delivered to your inbox |
| 31 |
Get BioPharma Dive in your inbox |
25702
